计算机科学
人工智能
数字化病理学
一致性
细胞角蛋白
组织病理学
医学
病理
危险分层
免疫组织化学
内科学
作者
Ansh Kapil,Armin Meier,Keith Steele,Marlon C. Rebelatto,Katharina Nekolla,Alexander Haragan,Abraham Silva,Aleksandra Żuraw,Craig Barker,Marietta Scott,Tobias Wiestler,Simon Lanzmich,Günter Schmidt,Nicolas Brieu
出处
期刊:IEEE Transactions on Medical Imaging
[Institute of Electrical and Electronics Engineers]
日期:2021-09-01
卷期号:40 (9): 2513-2523
被引量:10
标识
DOI:10.1109/tmi.2021.3081396
摘要
We report the ability of two deep learning-based decision systems to stratify non-small cell lung cancer (NSCLC) patients treated with checkpoint inhibitor therapy into two distinct survival groups. Both systems analyze functional and morphological properties of epithelial regions in digital histopathology whole slide images stained with the SP263 PD-L1 antibody. The first system learns to replicate the pathologist assessment of the Tumor Cell (TC) score with a cut-point for positivity at 25% for patient stratification. The second system is free from assumptions related to TC scoring and directly learns patient stratification from the overall survival time and event information. Both systems are built on a novel unpaired domain adaptation deep learning solution for epithelial region segmentation. This approach significantly reduces the need for large pixel-precise manually annotated datasets while superseding serial sectioning or re-staining of slides to obtain ground truth by cytokeratin staining. The capacity of the first system to replicate the TC scoring by pathologists is evaluated on 703 unseen cases, with an addition of 97 cases from an independent cohort. Our results show Lin's concordance values of 0.93 and 0.96 against pathologist scoring, respectively. The ability of the first and second system to stratify anti-PD-L1 treated patients is evaluated on 151 clinical samples. Both systems show similar stratification powers (first system: HR = 0.539, p = 0.004 and second system: HR = 0.525, p = 0.003) compared to TC scoring by pathologists (HR = 0.574, p = 0.01).
科研通智能强力驱动
Strongly Powered by AbleSci AI